Also known as: Delta Sleep-Inducing Peptide, Delta-Sleep-Inducing Peptide, DSIP Nonapeptide
Sleep quality improvement and insomnia management
Amount
100-300 mcg subcutaneous; 25 nmol/kg IV (~1.5 mg for 70 kg person)
Frequency
Once daily before bed; or every 2-3 days
Duration
10-30 days; effects may persist 3-7 months after a 10-day course
Route
SCSchedule
Once daily before bed; or every 2-3 days
Timing
Evening, 30-60 minutes before desired sleep onset; some sources suggest 2-3 hours before bed
✓ Rotate injection sites
Duration
10-30 days; effects may persist 3-7 months after a 10-day course
Repeatable
Yes
Course-based protocol with rest periods
Diluent: Bacteriostatic water
Use within: 24 hours
Storage: Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be used promptly or stored at 2-8C for no more than 24 hours. DSIP is susceptible to degradation in solution.
CBC
When: Baseline
Why: General health baseline
CMP
When: Baseline
Why: Liver and kidney function
Cortisol (morning)
When: Baseline
Why: DSIP may modulate cortisol and stress hormones
Cortisol
When: 2 weeks
Why: DSIP has been reported to normalize cortisol levels
Morning cortisol
When: Ongoing
Why: DSIP normalizes stress hormones; significant changes warrant monitoring
⚠️ DSIP normalizes stress hormones; significant changes warrant monitoring
Get weekly peptide research summaries, new study alerts, and protocol updates — free.
150+ peptide profiles · 30+ comparisons · 18 research tools
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide that was first isolated from the cerebral venous blood of rabbits in 1977 by the Schoenenberger-Monnier research group in Basel, Switzerland. The peptide has the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu with a molecular weight of approximately 849 Da. It was named for its ability to induce delta-wave (slow-wave) sleep when infused into the cerebral ventricles of recipient rabbits.
DSIP is normally synthesized in the hypothalamus and is present in minute amounts in the blood. Brain and plasma DSIP concentrations exhibit a marked diurnal variation, with concentrations being lower in the mornings and higher in the afternoons, suggesting a role in circadian rhythm regulation. The peptide has been found in numerous mammalian tissues and in the blood of various species including humans.
The mechanism of action of DSIP remains incompletely understood, which has been described as "a still unresolved riddle" in the scientific literature. Unlike many neuroactive peptides, DSIP does not appear to act through a single identified receptor. Instead, its effects appear to be mediated through multiple pathways.
DSIP has been demonstrated to promote delta-wave sleep in rabbits, mice, rats, cats, and humans. The peptide increases the proportion of slow-wave sleep characterized by high-amplitude delta rhythms on electroencephalography (EEG). In human studies, DSIP administration has been associated with increased sleep efficiency, shortened sleep latency, and normalization of disturbed sleep patterns. The sleep-promoting effects appear to involve modulation of serotonergic and GABAergic neurotransmission.
DSIP modulates the release of several hormones including luteinizing hormone (LH), growth hormone (GH), and adrenocorticotropic hormone (ACTH). These neuroendocrine effects suggest that DSIP acts at the hypothalamic level to influence pituitary hormone secretion. DSIP has been shown to suppress the stress-induced rise in cortisol and ACTH, suggesting an anti-stress or adaptogenic function.
In animal studies, DSIP has demonstrated analgesic properties when administered intracerebroventricularly or intracisternally, with a potent antinociceptive effect in mice. The peptide has also shown anticonvulsant activity, significantly decreasing the incidence and duration of seizures in rats with metaphit-induced epilepsy. These effects suggest broad neuromodulatory activity extending beyond sleep regulation.
Research has identified antioxidant properties of DSIP, including the ability to decrease lipid peroxidation and normalize antioxidant enzyme activities. These cytoprotective effects may contribute to the observed neuroprotective properties in experimental models of brain injury and oxidative stress.
The primary clinical interest in DSIP has been its potential for treating insomnia and other sleep disorders. Several small clinical studies have evaluated DSIP in patients with chronic insomnia, with variable results. Some studies reported normalization of sleep architecture and improved subjective sleep quality, while others found limited therapeutic benefit compared to placebo.
DSIP has been investigated for its stress-modulating properties, including the ability to attenuate the cortisol response to psychological and physical stress. This has led to interest in DSIP as a potential adaptogenic agent, though clinical evidence remains limited.
Small studies have explored DSIP as an adjunct in the management of opioid and alcohol withdrawal, based on its sleep-promoting and stress-modulating properties. Preliminary results have been encouraging but are insufficient to draw firm conclusions about efficacy.
DSIP is not approved for therapeutic use by any major regulatory agency. The clinical evidence base consists primarily of small, heterogeneous studies with mixed results. The peptide's mechanism of action remains incompletely characterized, and its pharmacokinetics following different routes of administration are not well established.
Despite more than four decades of research, fundamental questions about DSIP remain unresolved. The absence of an identified specific receptor, the inconsistency of clinical results across studies, and the limited understanding of its pharmacokinetics represent significant gaps. Large-scale, placebo-controlled clinical trials have not been conducted, and the optimal dosing, route of administration, and treatment duration have not been established.
The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide, published in Experientia (Schoenenberger GA et al., 1977; PMID: 862769):
Original characterization of DSIP comparing the naturally isolated peptide with its synthetic counterpart, confirming identical sleep-inducing properties.
Delta sleep-inducing peptide (DSIP): a still unresolved riddle, published in Journal of Neurochemistry (Kastin AJ et al., 2006; PMID: 16539679):
Comprehensive review examining the inconsistencies and unresolved questions in DSIP research, including its mechanism of action and clinical relevance.
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study, published in Neuropsychobiology (Schneider-Helmert D and Schoenenberger GA, 1983; PMID: 1299794):
Double-blind study examining DSIP effects in chronic insomnia patients, finding improvements in sleep efficiency and latency.
A clinical trial with DSIP, published in European Neurology (Schneider-Helmert D, 1984; PMID: 6391926):
Clinical evaluation of DSIP in patients with insomnia, assessing both objective and subjective sleep parameters.
Acute and delayed effects of DSIP on human sleep behavior, published in International Journal of Peptides and Protein Research (Schneider-Helmert D and Schoenenberger GA, 1983; PMID: 6895513):
Examined immediate and delayed sleep effects of DSIP administration in humans, finding normalization of sleep structure.
We summarize new studies, safety updates, and dosing insights — delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 80+ community reports
View community protocolsDSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood in 1977. It is an amphiphilic peptide with a molecular weight of approximately 849 Da that has been studied for its effects on sleep architecture, stress modulation, pain perception, and neuroendocrine regulation.
Research suggests the following potential benefits of DSIP: Studied for promotion of delta (slow-wave) sleep in multiple species. Research suggests stress-modulating and adaptogenic properties. Investigated for analgesic and anticonvulsant effects. Generally well-tolerated in limited human studies. These findings are based on available studies and the evidence level varies across different applications.
DSIP is primarily studied for: Sleep regulation research, Stress response modulation studies, Neuroendocrine function investigations. Research is ongoing and the evidence base continues to develop. Not all potential applications have been validated in human clinical trials.
Reported side effects of DSIP include transient headache, nausea, vertigo or dizziness. Most reported side effects are mild and transient. Comprehensive human safety data may be limited. Consult the detailed side effects profile for full information.
DSIP is currently in the preclinical stage. In the United States, it is classified as unregulated. Not FDA approved; sold as research chemical; not a controlled substance Regulations vary by country and may change.
Research-grade suppliers verified by our scoring methodology.
Cortistatin (CST-14): brain-specific neuropeptide that promotes slow-wave sleep, modulates inflammation, and shares structural homology with somatostatin. Preclinical research review.
Dermorphin: Potent frog-derived opioid peptide with 40x morphine selectivity. Covers mu-opioid mechanism, analgesic research, and safety concerns.
Humanin: 24-amino acid mitochondrial-derived peptide with anti-apoptotic and neuroprotective effects. Research in Alzheimer's, aging, and metabolic disease.
Neuropeptide Y (NPY): 36-amino acid endogenous peptide regulating stress resilience, appetite, and anxiety. Intranasal delivery studied for depression and PTSD.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Cortistatin has the superior mechanistic profile, with a well-defined receptor pharmacology, clear sleep-promoting mechanism through cortical synchronization, and endogenous homeostatic sleep factor properties. DSIP has more human data, but that data is old, inconsistent, and methodologically limited. Neither peptide has undergone modern clinical development for sleep. For research into sleep mechanisms, cortistatin offers a more tractable pharmacological target. For practical accessibility, DSIP is currently more available but with weaker mechanistic understanding. Both remain investigational with insufficient evidence for clinical sleep applications.
Oveporexton (TAK-861) is the clear winner on scientific evidence, having demonstrated statistically significant efficacy across multiple Phase 3 trials for narcolepsy type 1, with a well-characterized mechanism targeting the orexin receptor 2. DSIP remains a research peptide with limited and outdated clinical evidence. However, these peptides address fundamentally different conditions -- oveporexton targets narcolepsy-related wakefulness deficits while DSIP aims to promote deeper sleep in insomnia. They are not direct substitutes. For narcolepsy, oveporexton represents a potential breakthrough. For general sleep optimization, DSIP remains investigational with insufficient evidence to recommend clinical use.
A 2026 research-focused review of the peptides most often discussed alongside retatrutide for GI side effects, lean-mass preservation, hair and skin changes, sleep, and adjunct fat loss — what the literature does and does not support.
Understand the FDA peptide classification system. Learn the difference between Category 1, Category 2, and Category 3 peptides and what the 2024-2026 regulatory changes mean for researchers.
Research guide covering peptides studied for menopause symptoms including hot flashes, bone loss, cognitive changes, skin aging, sleep disruption, and hormonal regulation.
A comprehensive decision framework to help beginners identify the right peptide for their goals. Maps 10 health categories to specific peptide recommendations with evidence levels, administration routes, and regulatory context.
Related content you may find interesting